Headquarters: Boston, Massachusetts, USA
Founded: 2018
Status: Clinical/Preclinical
Focus: Age-related diseases, Neurodegeneration, Ophthalmology
Ticker: NASDAQ: LIFE
Life Biosciences is a biotechnology company focused on developing therapeutics for age-related diseases, with a particular emphasis on neurodegeneration and ocular diseases. Founded in 2018, the company takes a multi-target approach to address the underlying mechanisms of aging, including mitochondrial dysfunction, protein aggregation, and cellular senescence.
The company's name reflects its mission to extend healthy life by targeting the fundamental biological processes that drive age-related decline. Life Biosciences operates at the intersection of longevity science and pharmaceutical development, leveraging insights from aging research to develop disease-modifying therapies for conditions like Alzheimer's disease, Parkinson's disease, and age-related macular degeneration.
¶ Business Model and Strategy
Life Biosciences operates as a clinical-stage biotechnology company with a focus on:
- Platform-based drug discovery: Developing proprietary molecules targeting multiple hallmarks of aging
- Indication expansion: Repositioning pipeline assets across multiple age-related conditions
- Academic partnerships: Collaborating with leading research institutions on mechanism of action
Life Biosciences competes with several longevity-focused biotech companies including:
- Calico Life Sciences (Alphabet subsidiary)
- Unity Biotechnology (senolytics)
- BioAge Labs (aging biomarkers)
- Clever Biosciences (DNA repair)
¶ Pipeline and Programs
| Program |
Indication |
Stage |
Mechanism |
| LB-1 |
Alzheimer's Disease |
Preclinical |
Mitochondrial uncoupling |
| LB-2 |
Parkinson's Disease |
Preclinical |
Protein aggregation modulation |
| LB-3 |
Age-related macular degeneration |
Preclinical |
Senolytic approach |
| LB-4 |
Glaucoma |
Discovery |
Mitochondrial protection |
| LB-SIRT1 |
Alzheimer's/Parkinson's |
Discovery |
SIRT1 activator (NAD+ dependent) |
Life Biosciences is developing an SIRT1 activator program for neurodegenerative diseases:
Rationale:
- SIRT1 is an NAD+-dependent deacetylase that promotes mitochondrial biogenesis, reduces neuroinflammation, and protects against protein aggregation
- In Parkinson's disease, SIRT1 activity is reduced in dopaminergic neurons
- Activation of SIRT1 can deacetylate α-synuclein, reducing its aggregation propensity
- SIRT1 also deacetylates PGC-1α, enhancing mitochondrial biogenesis—a key therapeutic target for PD
Mechanism:
flowchart TD
A["SIRT1 Activator"] --> B["SIRT1 Activation"]
B --> C["PGC-1α Deacetylation"]
B --> D["FOXO Deacetylation"]
B --> E["α-Syn Deacetylation"]
B --> F["NF-κB Inhibition"]
C --> G["Mitochondrial Biogenesis"]
D --> H["Stress Gene Expression"]
E --> I["Aggregation Reduction"]
F --> J["Inflammation Reduction"]
G --> K["Neuronal Survival"]
H --> K
I --> K
J --> K
Differentiation:
- Novel SIRT1 activator with improved brain penetration
- Combined approach: direct SIRT1 activation + NAD+ augmentation potential
- Addresses both protein aggregation and mitochondrial dysfunction
See SIRT1 Activators for Parkinson's Disease for detailed mechanism.
The LB-1 program targets mitochondrial dysfunction, which is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. The approach involves:
- Mechanism: Small molecule mitochondrial uncouplers that restore proper cellular energy metabolism
- Rationale: Mitochondrial dysfunction is observed in Alzheimer's brains, leading to reduced ATP production and increased oxidative stress
- Differentiation: Unlike amyloid-targeting approaches, LB-1 addresses the downstream consequences of protein aggregation
The LB-2 program focuses on protein aggregation modulation in Parkinson's disease:
- Mechanism: Modulation of protein homeostasis pathways to reduce toxic protein aggregation
- Target: Alpha-synuclein aggregation and related pathology
- Rationale: Protein aggregation is a hallmark of Parkinson's disease, and current approaches have shown limited efficacy
The LB-3 program applies senolytic approaches to ocular diseases:
- Mechanism: Selective elimination of senescent cells in the retina
- Target: Age-related macular degeneration (AMD)
- Rationale: Senescent cells accumulate in the retina with age and contribute to AMD pathogenesis
Life Biosciences employs a platform approach targeting multiple hallmarks of aging:
Developing mitochondrial uncouplers to restore cellular energy metabolism. The company's mitochondrial platform builds on research showing that:
- Mitochondrial function declines with age in most tissues
- Restoring mitochondrial function can improve cellular health
- Small molecule uncouplers can improve metabolic parameters in disease models
Targeting protein aggregation pathways common to neurodegenerative diseases:
Senolytic and senostatic approaches to eliminate or modulate senescent cells:
- Clearing accumulated senescent cells reduces inflammation
- Senostatic approaches modulate the senescence-associated secretory phenotype (SASP)
- Applications in both neurodegeneration and ocular diseases
The company's research focuses on:
- Alzheimer's Disease: Targeting amyloid-beta and tau pathology through novel mechanisms
- Parkinson's Disease: Addressing alpha-synuclein aggregation and mitochondrial dysfunction
- Ophthalmic diseases: Age-related macular degeneration and glaucoma programs
- Broader longevity: Platform applicable to multiple age-related conditions
¶ Partnerships and Funding
Life Biosciences has established:
- Academic collaborations: Partnerships with leading research institutions on mechanism of action
- Investor backing: Funding from investors focused on longevity research including:
- Juvenile Diabetes Research Foundation
- Options Health Ventures
- At Last Ventures
The company plans to advance programs through:
- Phase 1 trials in healthy volunteers
- Phase 2 proof-of-concept studies in patient populations
- Strategic partnerships for late-stage development and commercialization
Life Biosciences represents an emerging player in the longevity biotechnology space. Key opportunities and challenges include:
- Growing interest in aging research: Increased venture capital and pharmaceutical company interest in longevity
- Unmet medical need: Limited disease-modifying treatments for Alzheimer's and Parkinson's
- Platform potential: Multi-indication approach provides multiple shots on goal
- Clinical development risk: Novel mechanisms may face regulatory uncertainty
- Competition: Multiple companies targeting similar mechanisms
- Funding environment: Biotechnology funding can be cyclical